Time to Treatment in Intracerebral Hemorrhage Across the United States
Abstract Body: Introduction: Contrary to improved mortality in acute ischemic stroke (AIS), mortality of intracerebral hemorrhage (ICH) remains high. This may be attributable to delays in acute treatments for ICH patients. We aimed to establish the current time to treatment in ICH patients across the U.S., compare this to AIS patients, and assess the impact of treatment times on outcomes.
Methods: This multicenter cross-sectional retrospective study pooled ICH and AIS patients aged ≥ 18 years with admission between January 1, 2017 to December 31, 2022 to acute care hospitals nationwide participating in the Get with the Guidelines-Stroke quality improvement registry. Baseline demographics, clinical variables including time to treatment (antihypertensive agent, hemostatic agent, neurosurgery, thrombolytic or thrombectomy) were abstracted and compared using classical statistics. Logistic regression and time dependent Cox analysis were performed to assess the impact of time to treatment on discharge disposition and mortality in ICH patients.
Results: We identified 3,344 ICH patients (mean (standard deviation) age 66(16) years, 43% female, and 5,386 AIS patients (mean (SD) 69(15) years, 48 % female) across eleven hospital systems. Median door to CT time was significantly longer in ICH compared with AIS patients at 26[12-69] vs14[8-25] minutes. Median NIHSS for ICH patients was significantly higher (13[5-25]) than AIS patients (10[4-18]). In ICH patients, median[IQR] arrival systolic blood pressure (SBP) was 179[160-205] mm HG and anticoagulation (AC) use was documented in 13.8%. Door to first treatment was 67[32-246] minutes for ICH patients and 55[35-114] minutes for AIS patients. ICH patients had a greater length of stay (7[3-14] days vs 5[2-9] days) and a higher median discharge mRS (4[3-6] vs 3[1-4]), p < 0.01 for all). Controlling for age, gender, race/ethnicity, NIHSS score, door to ED evaluation, prior AC use, arrival SBP and admission INR, the 1,047(31%) patients who were treated within 60 minutes from arrival had a higher likelihood of discharge to home or acute rehab; OR 1.73 95% CI (1.01-2.97). Time to antihypertensive treatment was a significant predictor of time to death with a hazard ratio (HR) of 1.22(1.03-1.45, p= 0.02).
Conclusion: Compared to AIS patients, time to treatment for ICH patients is generally longer. Faster treatment times were associated with better discharge outcomes. These findings emphasize the need for improved time metrics in ICH care.
Melmed, Kara
( NYU Langone Health
, New York
, New York
, United States
)
Krishnamohan, Prashanth
( STANFORD UNIVERSITY
, Palo Alto
, California
, United States
)
Subramaniam, Thanujaa
( Brown University
, Providence
, Rhode Island
, United States
)
Stretz, Christoph
( Brown University
, Providence
, Rhode Island
, United States
)
Lee, Wen-yu
( NYU Langone Health
, New York
, New York
, United States
)
Kuohn, Lindsey
( NYU Langone Health
, New York
, New York
, United States
)
Fong, Christine
( Harborview Medical Center
, Seattle
, Washington
, United States
)
Houghton, Margaret
( University of Kansas Health System
, Leavenworth
, Kansas
, United States
)
Campbell, Alexis
( MASSACHUSETTS GENERAL HOSPITAL
, Lynnfield
, Massachusetts
, United States
)
Song, Shlee
( CEDARS-SINAI MEDICAL CTR
, Los Angeles
, California
, United States
)
O'phelan, Kristine
( University of Miami , Neurology
, Miami
, Florida
, United States
)
Lele, Abhijit
( Harborview Medical Center
, Seattle
, Washington
, United States
)
Sheth, Kevin
( YALE UNIVERSITY SCHOOL OF MEDICINE
, New Haven
, Connecticut
, United States
)
Venkatasubramanian, Chitra
( STANFORD STROKE CENTER
, Palo Alto
, California
, United States
)
Yaghi, Shadi
( Brown University
, Providence
, Rhode Island
, United States
)
Mayer, Stephan
( New York Medical College
, Valhalla
, New York
, United States
)
Diaz, Ivan
( NYU Langone Health
, New York
, New York
, United States
)
Frontera, Jennifer
( NYU Langone Hospitals
, NYC
, New York
, United States
)
Ayodele, Mara
( UCSF Medical Center
, San Francisco
, California
, United States
)
Goldstein, Joshua
( MASSACHUSETTS GENERAL HOSPITAL
, Lynnfield
, Massachusetts
, United States
)
Lackamp, Aaron
( The University of Kansas
, Lenexa
, Kansas
, United States
)
Dombrowski, Keith
( USF
, Raleigh
, North Carolina
, United States
)
Alkhachroum, Ayham
( University of Miami
, Miami
, Florida
, United States
)
Mainali, Shraddha
( Virginia Commonwealth University
, Richmond
, Virginia
, United States
)
De Havenon, Adam
( Yale University
, New Haven
, Connecticut
, United States
)
Author Disclosures:
Kara Melmed:DO NOT have relevant financial relationships
| Prashanth Krishnamohan:DO have relevant financial relationships
;
Advisor:Vitaly Medical:Active (exists now)
| Thanujaa Subramaniam:No Answer
| Christoph Stretz:DO have relevant financial relationships
;
Other (please indicate in the box next to the company name):Massachusetts General Hospital/Boston Scientific:Past (completed)
| Wen-Yu Lee:DO NOT have relevant financial relationships
| Lindsey Kuohn:DO NOT have relevant financial relationships
| Christine Fong:DO NOT have relevant financial relationships
| Margaret Houghton:DO NOT have relevant financial relationships
| Alexis Campbell:DO NOT have relevant financial relationships
| Shlee Song:DO have relevant financial relationships
;
Advisor:Kandu:Active (exists now)
| Kristine O'Phelan:DO NOT have relevant financial relationships
| ABHIJIT Lele:DO NOT have relevant financial relationships
| Kevin Sheth:DO NOT have relevant financial relationships
| Chitra Venkatasubramanian:DO NOT have relevant financial relationships
| Shadi Yaghi:DO NOT have relevant financial relationships
| Stephan Mayer:DO NOT have relevant financial relationships
| Ivan Diaz:No Answer
| Jennifer Frontera:DO NOT have relevant financial relationships
| Mara Ayodele:DO NOT have relevant financial relationships
| Joshua Goldstein:DO have relevant financial relationships
;
Consultant:AstraZeneca:Active (exists now)
; Consultant:NControl:Past (completed)
; Consultant:Pfizer:Past (completed)
; Individual Stocks/Stock Options:Cayuga:Active (exists now)
; Consultant:Takeda:Active (exists now)
; Consultant:CSL Behring:Past (completed)
; Consultant:Octapharma:Active (exists now)
| Aaron LacKamp:DO NOT have relevant financial relationships
| Keith Dombrowski:DO have relevant financial relationships
;
Consultant:Samsung Neurologica:Active (exists now)
| Ayham Alkhachroum:DO NOT have relevant financial relationships
| Shraddha Mainali:DO NOT have relevant financial relationships
| Adam de Havenon:DO have relevant financial relationships
;
Research Funding (PI or named investigator):NIH/NINDS:Active (exists now)
; Researcher:UptoDate:Active (exists now)
; Individual Stocks/Stock Options:Certus:Active (exists now)
; Individual Stocks/Stock Options:TitinKM:Active (exists now)
; Consultant:Novo Nordisk:Active (exists now)
; Research Funding (PI or named investigator):AAN:Active (exists now)